Delivery Order SPE2DB24D1007-SPE2DB25FCCUR
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Trulicity 3 mg/0.5 ml pens valued at $13,213.91. This is a firm fixed-price delivery order with an ultimate completion date of August 6, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite...
- The Defense Logistics Agency awarded a $3,073.44 delivery order to AmerisourceBergen Drug Corp for Trulicity 1.5 mg/0.5 mL pens on August 4, 2025, with completion scheduled for August 5, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a single delivery order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's facility in Conshohocken,...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order on August 13, 2025, valued at $1,201.20 for the supply of Trulicity 3 mg/0.5 ml pens (0.5 ml units). This is a firm fixed price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of August 14, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Trulicity is a diabetes medication commonly used to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Trulicity 3 mg/0.5 mL pens valued at $1,368.55. This delivery order represents a firm fixed-price contract with no set-aside designation, indicating it was competitively awarded. The contract is set for ultimate completion on August 13, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award is a child...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Trulicity 3 mg/0.5 ml pens valued at $1,417.72 on July 18, 2025, with an ultimate completion date of July 21, 2025. This competitive, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vehicle running through December 2026. The product will be...
- The Defense Logistics Agency awarded a delivery order valued at $1,514.37 to AmerisourceBergen Drug Corp for the supply of Trulicity 1.5 mg/0.5 mL pens on August 12, 2025, with an ultimate completion date of August 13, 2025. This contract represents a firm fixed-price delivery order with no set-aside designation, issued under a competitive procurement process. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, the location of AmerisourceBergen's corporate office and...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Trulicity 3 mg/0.5 mL pens with a ceiling value of $1,719.90. This is a firm fixed price, non-set-aside contract scheduled for completion by July 28, 2025, with performance taking place at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Trulicity is a diabetes medication used for glycemic control, reflecting the company's substantial role in supplying...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Trulicity 3 mg/0.5 mL pens valued at $6,354.48 under a firm fixed-price contract. This non-set-aside delivery order, which is due for completion by July 30, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $1,801.80 to AmerisourceBergen Drug Corp for the supply of Trulicity 3 mg/0.5 ml pens on August 14, 2025. This firm fixed-price delivery order, issued under a non-competitive, non-set-aside procurement, represents a single fulfillment against AmerisourceBergen's larger pharmaceutical supply contract with DLA. The product will be delivered to the company's headquarters in Conshohocken, Pennsylvania, with a completion deadline of...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,592.05 to AmerisourceBergen Drug Corp for the supply of Trulicity 3 mg/0.5 mL pens on August 14, 2025, with an ultimate completion date of August 15, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement supporting federal medical supply needs. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a...
- SPE2DB24D1007Indefinite Delivery Contract
- SPE2DB24D1007-SPE2DB25FCCURDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Trulicity 3 mg/0.5 mL pens with a contract value of $3,903.90. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded contract. The order is set for ultimate completion by August 12, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Trulicity, a diabetes medication, represents one of many pharmaceutical products that AmerisourceBergen supplies through its federal contracts. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and critical federal medical supplier, AmerisourceBergen leverages this comprehensive IDC to fulfill military and federal healthcare needs across multiple therapeutic categories. The parent IDC enables the company to provide a broad range of pharmaceutical products and medical supplies to support military healthcare programs globally, including support for the Defense Health Agency and other government healthcare systems through flexible delivery orders such as this one.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.9k | 8/11/25 |